Substituted sulfonanilides in the treatment of inflammation

ABSTRACT

Benzoylhaloalkanesulfonanilides of the general type   WHEREIN Rx is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n&#39;&#39; are each 0-3. These compounds and their salts have valuable pharmacological activity as anti-inflammatory agents.

United States Patent 8 1 Robertson et al.

[ SUBSTITUTED SULFONANILIDES IN THE TREATMENT OF INFLAMMATION [75] inventors: Jerry E. Robertson, North Oaks;

Joseph K. Harrington, Edina; Donald C. Kvam, North Oaks, all of Minn.

[73] Assignee: Riker Laboratories, Inc., Northridge,

Calif.

[22] Filed: May 24, 1972 [21] App]. No.: 256,377

Related US. Application Data [52] US. Cl. 424/324 [51] Int. Cl. A6llt 27/00 [58] Field of Search 424/321 Primary Examinr- Stanley J. Friedman AtzorneyKinney, Alexander, Sell, Steldt & Delahunt [111 3,758,688 1 Sept. 11, 1973 [57] ABSTRACT Benzoylhaloalkanesulfonanilides of the general type wherein R, is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n are each 03. These compounds and their salts have valuable pharmacological activity as anti-inflammatory agents.

I 17 Claims, No Drawings SUBSTITUTED SULFONANILIDES IN THE TREATMENT OF INFLAMMATION This application is a continuation-in-part of copending application Ser. No. 45,413, filed June 11, 1970, now abandoned, which is a division of application Ser. No. 832,824, now U.S. Pat. No. 3,576,866, filed June 12, 1969 which in turn was a continuation-in-part of the copending applications Ser. No. 588,338, filed Oct. 21, 1966 and Ser. No. 719,741, filed Apr. 8, 1968, both are now abandoned.

The invention relates to haloalkanesulfonanilides which have valuable pharmacological activity. Steroids having cortisone-like activity have heretofore been used for treatment of inflammatory, e.g. arthritic conditions. While these are effective, they have certain undesirable side effects. Consequently, there is a need for effective anti-inflammatory agents which are free of such disadvantages.

The novel and efficacious compounds of the present invention are non-steroidal in character, and their use does not entail side effects peculiar to steroid therapy. Of particular value in the anti-inflammatory compounds of the present invention is their relatively low toxicity, and they are well tolerated by the gastrointestinal tract. A number of the new compounds alsohave anti-pyretic and analgesic activity. The pharmacological activities of these compounds have been elucidated by means of mammalian animal tests.

The present invention contemplates providing a novel class of pharmacologically active compounds, especially com-pounds with anti-inflammatory activity. The invention further aims to provide compositions of the novel, active compounds which are suitable for administration for pharmacological purposes. Within the purview of the invention are processesfor the preparation and use of the compounds of the inventionfor pharmacological purposes. Still other objectives of the invention will become apparent to those skilled in'the art from reading the following disclosure. 7

The novel benzoylhaloalkanesulfonanilides of the invention (which may also be termed haloalkylsulfonamidobenzophenones) have the formula:

Formula 1 wherein R, is a haloalkyl group having up to four carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is hydrogen, 'alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable cation; each Y is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n are each -3.

Unless otherwise specified, in the compounds of the invention, the various halogen atoms in an R, group can be the same or different, the various Y groups can be the same or different (regardless of whether they occur as substituents on the same ring or on the two different rings) and n and n can be the same or different. When n and n' are both zero, the rings will be unsubsti- Yn Y tuted, i.e. the compounds will have the formulae:

The compounds of formula 1 have anti-inflammatory action when tested by standard test methods using animals, as described more particularly hereinafter.

Compounds of this invention wherein R contains up to two carbon atoms are presently preferred, and those in which R, contains one carbon atom are most preferred. Compounds wherein the halogen in the R, is fluorine and/or chlorine are presently preferred, particularly wherein the halogen therein is all fluorine (especially compounds in which R, is HCF, or H,CF'). The compounds in which R. is perfluorinated also form a preferred group, particularly trifluoromethyl.

Preferably in the foregoing groups and other compounds of the invention, the haloalkylsulfonamido group in the com-pounds of the invention is oriented meta to the carbonyl group.

The compounds in which n and n are zero, or in which one of them is zero and the other is one and the Y or Y is hydroxy have outstanding anti-inflammatory activity and therefore also form a preferred class.

When R is alkyl, it is preferred that R is methyl or ethyl. When Y and/or Y are alkyl or alkoxy, it is preferred that the alkyl and alkoxy groups contain one carbon atom. Similarly when Y and/or Y are haloalkyl or haloalkoxy, it ispreferred that they contain one carbon atom. I

The products of the present invention are effective anti-inflammatory agents and some also are analgesic and anti-pyretic agents. The anti-inflammatory activity can be conveniently demonstrated using assays designed to test the ability of these compounds to antagonize the local edema which is a characteristic of the anti-inflammatory response (rat foot edema test) and to inhibit the onset of the erythematous manifestation of inflammation (guinea pig erythema test).

The edema test is performed on adult female rats. One group of 10 rats serves as non-medicated controls, while another group of 10 rats receives the test compound at various times'prior to the induction of the edema, usually 15 minutes, one hour and/or 18 hours. The test compound is administered as a suspension in 4 percent aqueous solution of acacia. Edema is induced by the plantar injection of 0.5 percent carrageenin (0.1 ml./foot) into the right hind foot. The left hind foot receives a like volume of 0.9 percent saline solution. One hour later, the volume of each hind foot .is determined plethysmographically. The edema is expressed as the increase in the volume of the edemogen injected foot (volume of the edemogen foot less the volume of the saline foot). The percent inhibition is calculated by dividing the mean increase in the edema of the edemogen foot of the medicated group by the mean increase in the non-medicated group, multiplied by 100.'An active dose is that giving a statistically significant inhibition of the induced edema, usually about 30-35 percent, inhibition.

Leading references to this method are:

l. Adamkiewicz et al., Canad. J. Biochem. Physio.

2. Selye, Brit. Med. J. 221129, 1949; and

3. Winter, Proc. Soc. Exper. Biol. Med. 1111544,

The erythema test is performed on adult, albino guinea pigs of either sex weighing 400-600 g. Hair is removed from the abdomen of the animals by a depilatory mixture the afternoon of the day prior to the day on which they are to be used. One group of 5 animals serves as non-rnedicated controls, while another group of 5 receives the test compound 30 minutes prior to direct exposure to ultraviolet light. For inducation of erythema, the animal is restrained on a small animal board. Three circular sections (6-8 mm. in diameter) of the ventrolateral abdominal area of the animal are 7 then exposed to a controlled amount of ultraviolet radiation. Two hours after exposure, the erythema is scored 0-5 on the basis of its intensity and completeness (full or partial circles). The maximal score per animal is 15. The percent inhibition is calculated on the basis of the mean score for the medicated group versus the non medicated group. An active dose is taken to be that giving a statistically significant inhibition of the induced erythema, usually 35-40 percent inhibition. Modifications of this test include variation in the time and method of drug administration.

Leading references to this method are:

l. Wilhelm, Schweiz. Med. Wschr. 25:577, 1949, and

2. Winder et al., Arch. Int. Pharmacodyn. 1161261,

In the rat foot edema test and/or the guinea pig ery-' thema test, the following compounds have been found to be effective anti-inflammatory agents (i.e., to have significant activity) at dosage levels of [00 mg/kg or less in single doses:

3-benzoyldifluoromethanesulfonanilide, 3-benzoyldifluoromethanesulfonanilide, sodium salt, 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide, S-benzoylfluoromethanesulfonanilide, 3-(4-chloro-2-methylbenzoyl)trifluoromethanesulfonanilide, N-methyl-3-benzoyltrifluoromethanesulfonanilide, N-ethyl-3-benzoyltrifluoromethanesulfonanilide, 3-(4-methylbenzoyl)fluoromethanesulfonanilide, 3-(4-chlorobenzoyl)difluoromethanesulfonanilide, 3-benzoyl-2,2,2-trifiuoroethanesulfonanilide, 3-(4-methoxybenzoyl)difluoromethanesulfonanilide, 3-(4-methoxybenzoyl)fluoromethanesulfonanilide, 4-benzoyldifluoromethanesulfonanilide, 3-(2-hydroxybenzoyl)trifluoromethanesulfonanilide, 3-benzoyltrifluoromethanesulfonanilide, 4-benzoyltrifluoromethanesulfonanilide, 3-(4-methylbenzoyl)trifluoromethanesulfonanilide, 3-(4-1methoxybenzoyl)trifluoromethanesulfonanilide, 3-(4-chlorobenzoyl)trifluoromethanesulfonanilide, 3-(3-chlorobenzoyl)trifiuoromethanesulfonanilide, 3-(2-chlorobenzoyl)trifiuoromethanesulfonanilide, 3-(2-methylbenzoyl)trifluoromethanesulfonanilide, 3-benzoylperfluoroethanesulfonanilide, 3-(4-fluorobenzoyl)trifluoromethanesulfonanilide, 3-benzoyl-4-chlorotrifluoromethanesulfonanilide, 3-benzoyl-(2-hydroperfluoroethane)sulfonanilide, 3-benzoyl-4-chlorodifluoromethanesulfonanilide, 4-chloro-3-(4-chlorobenzoyl)trifluoromethanesulfonanilide, 4-chloro-3-(4-fluorobenzoyl)trifluoromethanesulfonanilide, 3-(4-fluorobenzoyl)difluoromethanesulfonanilide, 3-benzoylchloromethanesulfonanilide,

4 4-chloro-3(4-fiuorobenzoyl)difluoromethanesulfonanilide, and 4-chloro-3-(4-chlorobenzoyl)difiuoromethanesulfonanilide.

Aspirin, which is very widely used as an antiinflammatory agent, is only marginally active at 150 mg/kg in the rat foot edema test.

The compounds named hereinabove, and their salts are made by the general process describd hereinbelowand as further specifically illustrated in the Examples The compounds are preferably administered orally as anti-inflammatory agents but other known methods of administration are contemplated as well, e.g. dermatomucosally (for example dermally, rectally, and the like) and parenterally, for example by subcutaneous injection, intramuscular injection, intravenous injection and the like. Ocular administration is also included. Dosages ordinarily fall within the range of about 1 to 500 mg./kg. of body weight of the mammal to be treated although oral dosages are not usually above 100 mg./kg. and injection dosages are not usually above 50 mg./kg. Suitable forms for oral administration include liquids (such as four percent acacia suspensions), tablets (which may contain anhydrous lactose, microcrystalline cellulose, modified starch, calcium stearate and talc, as well as other conventional compounding agents together with the active anti-inflammatory agent) and capsules. Suitable carriers for topical application include creams, gels, tapes and the like. Liquid formulations, such as, solutions or suspensions of the active ingredient in inert carriers, are contemplated for dosage by injection.

Some of the compounds of the invention have been found to be quite active when administered derrnally. When formulated as a cream (eg as a v5 percent. cream), 5-benzoyldifluoromethanesulfonanilide has been found to inhibit erythema of guinea pigs exposed to ultraviolet light as described in the erythema test. The cream is administered to the skin after exposure to the ultraviolet light.

To produce the compounds of Formula I, wherein R is hydrogen, an aminobenzo'phenone is condensed with a haloalkylsulfonyl halide oranhydride according to the following scheme:

wherein R, n, n and Y are as previously defined and X represents a halogen atom, preferably chlorine'or fluorine, or the corresponding anhydride grouping OSO R, (R being defined as above). Approximately dimcthylaniline. The amount of the acid acceptor can be varied widely; however, a 10 mole percent excess of that amount of base sufficient to bind the liberated strong acid (HX) is routinely employed.

The condensation is usually conducted in the presence of an appropriate inert organic solvent. Typical solvents suitable for this purpose are methylene chlo ride, chloroform, carbon tetrachloride, benzene, toluene, bis(2-methoxyethyl) ether, acetonitrile, nitromethane, and the like.

After reaction is complete, if the reaction solvent is not water miscible, the product mixture can be extracted with a dilute aqueous base solution. The prodbet, in the form of a salt which is usually soluble in the aqueous layer, is precipitated therefrom by addition of a mineral acid such as hydrochloric or sulfuric acid, and collected by filtration. Alternatively the product mixture can be washed with aqueous hydrochloric acid, the solvent evaporated in vacuo, and the residue dissolved in a dilute aqueous base solution which is washed with dichloromethane and treated with decolorizing charcoal. The product, in the form of a salt is then isolated as described above.

If the reaction solvent is water miscible, the product is generally obtained by dilution of the reaction mixture with water. The product, a solid or oil, is separated and purified by conventional methods. The compounds prepared according to the foregoing procedures are crystalline solids purified, in general, by recrystallization from aqueous alcohol, trichloroethylene, hexane, benzene-hexane mixtures and the like. Elution chromatography has also been found to be a useful purification technique.

An additional and preferred method of obtaining the compounds of the invention in which Y is hydroxy is by cleavage of the alkoxy group of the comparable sulfonanilides in which Y is alkoxy. This can be done conveniently with hydrogen iodide-acetic acid mixtures. Alternatively, other known ether cleavage methods, e.g. hydrobromic acid-acetic acid, may be used.

When R is hydrogen in the compounds of the invention, this hydrogen is acidic in nature. Consequently, they readily form salts of alkali metals, alkaline earth metals, amines and the like. Pharmaceutically acceptable salts of these acidic compounds are included within the scope of Formula I, when R is a pharmaceutically accpetable cation.

Many of the salts are readily prepared by adding-the stoichiometric amount of the selected base in inert solvent solution to the acidic compound. The resulting solution is treated to remove the solvent, e.g. by evaporation under reduced pressure. The salts are conveniently used in making pharmaceutical preparations for administration of the compounds, e.g. in capsules for oral administration. Another method for the preparation of salts of the invention is the reaction of a salt of the invention with an organic or inorganic salt in a cation exchange reaction. I

Compounds of the invention wherein R is alkyl or alkenyl are readily prepared by the reaction of the compounds of the invention where R is hydrogen or a cation with an alkyl or alkenyl halide. This method for alkylation is known to the art.

Suitable haloalkanesulfonylanhydrides and halides (e.g. chlorides and fluorides) for use as starting materials in these procedures are known to the art, for example:

fluoromethanesulfonyl chloride,

fluorochloromethanesulfonyl chloride,

difluoromethancsulfonyl chloride,

dichloromethanesulfonyl chloride, 2,2,2-trifluoroethanesulfonyl chloride, trifluoromethanesulfonyl chloride,

l, l ,2,Z-tetrafluoroethanesulfonyl chloride,

bromomethanesulfonyl chloride,

2,2,3,3-tetrafluoropropanesulfonyl chloride, 2-hydroperfluoropropanesulfonyl chloride, and many others disclosed, e.g. in U. S. Pat. No. 2,732,398.

The aminobenzophenones used in producing the compounds of the invention are generally described in the chemical literature or can be prepared from corresponding known substituted nitrobenzophenones by reduction. Any nitrobenzophenones or aminobenzophenones not specifically disclosed in the chemical literature are prepared by methods known in the literature for analogous compounds. Exemplary of such starting materials are:

5-amino-2-chlorobenzophenone,

3-amino-4-fluorobenzophenone, 3-amino-5-bromobenzophenone, 3-amino-4'-ethylbenzophenone, 3-amino-2'-ethoxybenzophenone, 3-aminc-4-ethoxybenzophenone, etc.

The following examples are given for the purpose of further illustrating the present invention, but are not intended to limit the scope thereof. All melting and boiling points are uncorrected. All parts are by weight unless otherwise specified in the examples.

EXAMPLE 1 Preparation of 3-benzoylfluoromethanesulfonanilide A 500 ml. flask fitted with reflux condenser was charged with 8.7 g. of N,N-dimethylaniline (0.72 mole), a solution of 12.8, g. of 3-aminobenzophenone (0.065 mole) in 50 ml. of methylene chloride, 8.6 g. of fluoromethanesulfonyl chloride (0.065 mole, b.p. l38l4l C.) and 200 ml. of methylene chloride. The mixture was heated at reflux temperature overnight, then cooled, washed twice with 500 ml. portionsof l0 percent hydrochloric acid and dried over anhydrous magnesium sulfate. The solvent was removed by evaporation leaving an oil that crystallized after 3 hours in the vacuum oven to afford relatively pure product, m.p. ll6l 19 C. This solid was taken up in 300 ml. of 10 percent aqueous sodium hydroxide. The solution was warmed, treated with activated carbon and acidified to pH 1 with concentrated hydrochloric acid. An oil formed initially but crystallized to give a solid, m.p. ll5l 17 C. This was recrystallized from percent ethanol to give analytically pure product, m.p. l l7-l 20 C.

Analysis: Calculated for C H ,FNO,S: C, 57.3; H,

4.l Found: C, 57.7; H, 4.1.

EXAMPLE 2 Preparation of 3-benzoyldifluoromethanesulfonanilide A one liter flask fitted with reflux condenser was charged with 0.l mole of 3-aminobenzophenone, 10 ml. of pyridine, 0.1 mole of difluoromethanesulfonyl chloride, and 400 ml. of benzene. The mixture was heated at 5055 C. for 72 hours and then extracted with 10 percent aqueous sodium hydroxide. Acidification of the alkaline layer produced a solid which was recrystallized from trichloroethylene-hexane mixtures to afford analytically pure product, m.p. 99-100.5 C. Analysis: Calculated for C H F NQ-fiz C, 54.1; H,

3.6; N, 4.4 Found: C, 53.9; H, 3.6; N, 4.4.

EXAMPLE 3-32 By the use of the general procedure of Examples 1 and 2 and the substitution of other haloalkanesulfonyl chlorides and other substituted aminobenzophenone starting materials, all of which are known, the following exemplary compounds are obtained:

Example M.P. "C. No. (uncorrected) 3 2-benzoyldifluoromethanesulfonanilide 79.5-81 4 3-( 4-methylbenzoyl )difluoromethanesulfonanilide 1 19-121 5 3-(4-chlorobenzoyl )difluoromethanesulfonanilide 127-129 6 3-( 4-methoxybenzoyl )fluoromethanesulfonanilide l 16.5-1 18.5 7 3-benzoyl-4-chlorodifluoromethanesulfonanilide 99-102 8 3-benzoyl-4-ch1orof1uoromethanesulfonanilide 1 13-1 16 9 4-benzoyldifluoromethanesulfonanilide 1245-1265 10 2-benzoylfluoromethanesulfonanilide 74.5-75.5 1 1 3-( 4-chlorobenzoyl)fluoromethanesultonanilide 1 18-120 12 3-( 4-n-butoxybenzoyl)fluoromethanesulfonanilide 1 13-1 17 13 3-(4-t-butylbenzoyl )fluoromethanesulfonanilide 102-105 14 3-(4-fluorobenzoyl )ditluoromethanesulfonanilide 80-84 15 3-( 4-fluorobenzoyl )fluoromethanesulfonanilide 127-129.5 16 3-( 4-hydroxybenzoy1)difluoromethanesulfonanilide 150-152 Prepared by the method of Example 84 from the compound of Examp e 34.

butanelulfonanllide b.p. 186C./0.09 mm.

EXAMPLE 33 Preparation of the sodium salt of B-benzoyldifluoromethanesulfonanilide.

To a solution of 12.21 g. of reagent grade sodium hydroxide (0.305 mole) in 300 ml. of water were added 95 g. of 3-benzoyldifluoromethanesulfonanilide (0.305 mole). The mixture was stirred until dissolution was complete and the solution had pH 7.2 (sensitive pH paper). Water was removed to give a yellow solid which was taken up in about 200 ml. of glyme and treated with activated charcoal. The clear solution was then added dropwise with vigorous stirring to 5 liters of ethyl ether. The crystalline saltwas isolated by filtration, washed with 4 liters of ethyl ether and driedto give analytically pure product, m.p. (dec.) 235 C.

Analysis: Calculated for C H, F NaNO S: C, 50.45;

H, 3.05 Found: C, 50.6; H, 3.2

Other salts are made by the same process, substituting other alkali or alkaline earth metal hydroxides for sodium hydroxide. Amine salts are made using alcohol solutions of the stoichiometric amount of the amine, in

a similar manner, e.g. the dimethylaminoethanol salt. Alternatively, water solutions of the amine may be used.

EXAMPLE 34 Preparation of 3-(4-methoxybenzoyl)difluoromethanesulfonanilide A one liter flask fitted withreflux condenser was charged with 56.8 g. of 3-amino-4'- methoxybenzophenone (0.25 mole),.-26'.5 g. of N,N- dimethylaniline (0.30. mole), 37.8 g. of difluoromethanesulfonyl chloride (0.25 mole) and 350 ml. of methylene chloride. The mixture was heated at'reflux temperature for 36 hours and then was extracted with dilute aqueous sodium hydroxide. After treatment with charcoal, acidification of the alkaline extract afforded a solid which was washed with hot heptane and recrystallized from carbon tetrachloride-hexane mixtures to afford analytically pure product, m.p. ll8'-120'C.

Analysis: Calculated for C H F NO S: C, 52.8; H,

3.9; N, 4.1 Found: C, 52.6; H, 3.9; N, 4.2.

EXAMPLEzBS Preparation of 3-benzoyl-2,2,2-trifluoroethanesulfonanilide A one lifter flask was charged with-29.6 g. of 3- aminobenzophenone (0.15 mole), 9.2 g.- of 2,2,2-trifluoroethanesulfonyl chloride (0.05 mole),and 250 ml. of methylene chloride. The mixture was allowed to stand for about an hour with occasional shaking. The reaction mixture was then .washed with dilute hydrochloric, acid to remove excess 3- aminobenzophenone, and the solvent was removed by evaporation to afford a solid product. Recrystallization of the solid from trichloroethylene and drying gave analytically pure product, m.p. 105.5-107 C.

Analysis: Calculated for C, H,,F NO=,S: C, 52.5; H,

3.5; N, 4.1 Found: C, 52.7; H, 3.7; N, 4.1.

EXAMPLE 36 Preparation of 3-(4-methylbenzoyl)fluoromethanesulfonanilide g A 500 ml. flask fitted with reflux condenser was charged with 10.5 g. of 3-amino-4'- methylbenzophenone (0.03 mole), 6.7 g. of N,N- dimethylaniline (0.055 mole), 6.6 g.- of fluoromethanesulfonyl chloride (0.05 mole) and ml. of methylene chloride. The reaction mixture was heated at reflux temperature for 20 hours. Methylene chloride was then removed by evaporation, and the residue was extracted with dilute aqueous sodium hydroxide. The alkaline extract was washed witheethyl-ether, treated with charcoal and acidified. The precipitated solid was recrystallized from ethanol-water mixtures to give ana- EXAMPLE 37 Preparation of 3-benzoylperfluoroethanesulfonanilide A 300 ml. Parr pressure vessel was charged with 9.85 g. of 3-aminobenzophenone (0.05 mole), 150 ml. of triethylamine and 10.1 g. of perfluoroethanesulfonyl fluoride (0.05 mole). The mixture was heated at 90-100 C. for 24 hours.

Triethylamine was removed by evaporation, yielding an oil which was taken up in benzene. The benzene solution was washed with dilute hydrochloric acid and extracted with dilute sodium hydroxide. Acidification with hydrochloric acid affords a solid which was recrystallized from ethanol-water to give white, solid product, m.p. 95-97 C.

Analysis: Calculated for C H F NO S: C, 47.5; H,

2.7; N, 3.7 Found: C, 47.7; H, 2.8; N, 3.7.

EXAMPLES 38-42 By the use of the general procedures of Examples 34-37 and the substitution of other haloalkanesulfonyl anhydride and halide starting materials, the following exemplary compounds are obtained.

Example 38 3-benzoylfluorochloromethanesulfonanilide 39 3-benzoyl-1,1,3-trihydroperfluoropropanesulfonanilide 40 3-benzoyldichloromethanesulfonanilide 41 3-benzoyl-perfl uoroisopropanesulfonanilide 42 3-benzoylbromomethanesulfonanilide EXAMPLE 43 Preparation of 3-benzoyltrifluoromethanesulfonanilide Into a 3-necked, one liter flask equipped with stirrer, condenser, additional funnel, internal thermometer and nitrogen sweep were charged 59.8 g. of 3- aminobenzophenone (0.304 mole), 50.4 ml. of triethylamine and 400 ml. of chloroform. Trifluoromethanesulfonic anhydride was added slowly to the stirred mixture at -25 C. (ice-bath cooling). After stirring at room temperature for two hours, the solution was washed with dilute hydrochloric acid and then extracted with 10 percent aqueous sodium hydroxide. The aqueous extract was washed with chloroform until the washes were clear, clarified with charcoal, and aciditied to pH 1 with concentrated hydrochloric acid. The product was collected by filtration, washed with water and dried. Recrystallization from hexane afforded analytically pure product, m.p. 99-101 C.

Analysis: Calculated for c n nuo sz C, 5

3.1 Found: C, 51.3; H, 3.2.

EXAMPLES 44-83 By use of the procedure of Example 43 and the substitution of other aminobenzophenone starting materials, the following exemplary compounds were obtained: Y

Example M.P.- C. No. (uncorrected) 44 Z-benzoyltrifluoromethanesulfonanilide 98-100 45 4-benzoyltrifluoromethanesulfonamlide 136-137 46 3-(4-methylbenzoyl )trifluoromethanesulfonanilide 129.5-13l.5

10 47 3-(4-methoxybenzoyl)trifluoromethanesulfonanilide 122.5-1 24.5 48 3-( 4-fluorobenzoyl )trifluoromethanesulfonanilide 134-136 49 3-(4-chlorobenzoyl )trifluoromethanesult'onanilide 123.5-1255 50 5-benzoyl-2chlorotri fluoromethanesulfonanilide 102-103 51 3-benzoyl-5-chlorotrifluoromethanesulfonanilide 1 14-1 16 52 3-benzoyl-4-chlorotrifluoromethanesulfonanilide 106-108 53 3-benzoyl-2-chlorotrifluoromethanesulfonanilide 92-93 54 4-(2-chlorobenzoyl )trifluoromethanesulfonanilide 144.5l46.5 5 S 4-( 3-ch1orobenzoyl )ti ifluo romethanesulfonanilide 139-141 5 6 4-(4-chlorobenzoyl )trifluoromethanesulfonanilide 145-147 57 3-benzoyl-Z-methyltrifluoromethanesulfonanilide 1 19-121 58 5-benzoyl-2-methyltrifluoromethanesulfonanilide 84-85 59 3-benzoyl-5-methyltrifluoromethanesulfonanilide 94-96 60 3-( 3-methylbenzoyl )trifluoromethanesulfonanilide 91-93 61 2-( 3-methylbenzoyl)trifluoromethanesulfonanilide 92-93 62 3-(2,5-dimethoxybenzoyl)trifluoromethanesulfonanilide 121.5-124 63 4-chloro-3-(4-methylbenzoyl )trifluoromethanesulfonanilide 88-90 64 4-chloro-3-(4-methoxybenmyl)trifluoromethanesulfonanilide 89-90 65 4-chloro-3-(4-chlorobenzoyl(trifluoromethanesulfonanilide 82-83 66 4-chloro-3-( 4-fl uorobenzoyl )trifluoromethanesulfonanilide 13 3-134 67 3-( 2-methylbenzoyl )trifluoromethanesulfonanilide 92-93 68 4-chloro-2-(2-chlorobenzoyl )trifluoromethanesulfonanilide 86-88 69 3-( 3,4-dichloroben2oyl )trifluoromethanesulfonanilide 146-147 70 3-( 2,5-dimethylbenzoyl )trifluoromethanesulfonanilide 85-86 71 3-( 2,3-dirnethylbenzoyl)trifluoromethanesulfonanilide 107-109 72 3-benzoyl-4-methoxytrifluoromethanesult'onanilide 131-132 73 3-( Z-methoxybenzoyl)trifluoromethanesulfonanilide 87-89 74 3-( 2,6-dimethylben y1)trifluoromethanesu onanilide 1 13-1 14 75 3-(4-chloro-2-methylbenmy1)trifluoromethanesulfonanilide 135-137 76 S-benmyl-Z-methoxytrifluoromethanesulfonanilide 87-89 77 3-benzoyl-4-bromotrifluoromethanesulfonanilide 13 1 78 3-(3,4-dimethylbenzoy1)trifluoromethanesulfonanilide 129 79 3-(2,4-dimethylbcnzoymri-v lluoromethanesulfonanilide 106-108 80 3-(4-ethylbenzoyl )trifluoromethanesulfonanilide -91 8 l 3-(3-fluorobenzoyl)trifluoromethanesull'onanilide 96-98 82 3-benzoyl-2-methoxytrifluoromethanesulfonanilidc 132-1 33 83 3-benzoyl-S-methoxytrifluoromethanesulfonanilide 89-91 EXAM PLE 84 Preparation of 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide Glacial acetic acid (20 ml.), 55 percent hydroiodic acid (7 ml.) and 3-benzoyl-4-methoxytrifluoromethanesulfonanilide( 1.8 g., 5 mmole) were heated to reflux temperature and maintained at reflux for four hours. This reaction mixture was poured over ice, and the resulting mixture was extracted with dichloromethane. The dichloromethane layer was evaporated in vacuo to give a yellow solid. Recrystallization from benzenecyclohexane gave light yellow 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide, m.p. 133136 C.

Analysis: Calculated for C H F NO S: C, 48.7; H,

2.9; N, 4.1 Found: C, 49.1; H, 2.9; N, 4.0.

EXAMPLES 85-90 By use of the general procedure of Example 84 and the substitution of other benzoylmethoxysulfonanilides, the following exemplary compounds were obtained:

Example Melting Point No. (in C.) 85 3-(4-hydroxybenzoyl)trifluoromethanesulfonanilide 156-158 86 3-(B-hydroxybenzoyl)trifluoromethanesulfonanilide l69-l 72 87 -benzoyl-Z-hydroxytrifluoromethanesulfonanilide 178-181 88 3-benzoyl-5-hydroxytrifluoromethanesulfonanilide 128-130 89 3-benzoyl-2-hydroxytrifluoromethanesulfonanilide 86-88 90 3-( 2-hydroxybenzoyl)trifluoromethanesulfonanilide 131-133 EXAMPLE 91 Preparation of N-Ethyl-3-benzoyltrifluoromethanesulfonanilide Sodium carbonate (6.89 g., 0.082 mole) was dissolved in distilled water (70 ml.) and 3-benzoyltrifluoromethanesulfonanilide (27.0 g., 0.082 mole) was added in small portions. Water (30 ml.) was added and the solution was stirred for 3 hours. The solution was filtered and the filtrate was evaporated to dryness in vacuo. The solid was dissolved in ethanol, treated with decolorizing charcoal and filtered. The filtrate was evaporated to dryness in vacuo, and the solid sodium 3-benzoyltrifluoromethanesulfonanilide was dried.

Analysis: Calculated for C,,,H F NNaO S: C, 48.0; H,

2.6 Found: C, 48.0; H, 2.8.

Sodium 3-benzoyltrifluoromethanesulfonanilide (20 g., 57 mmole), acetone (250 ml.) and ethyl iodide (11.7 g. 75 mmole) were heated to reflux and maintained at reflux temperature for 1 day. The reaction mixture was evaporated to remove solvent and the oil obtained was dissolved in chloroform. The solution was washed twice with percent sodium hydroxide, twice with water and dried over magnesium sulfate; then treated with decolorizing charcoal and filtered. The solvent was removed in vacuo and the liquid product was distilled through a molecular still to give a light yellow liquid, N-ethyl-3-benzoyltrifluoromethanesulfonanilide, column temperature 170 C., pressure 1 X 10' mm. of mercury.

Analysis: Calculated for c,,H,,F,No,s: C, 53.8; H,

3.95 Found: C, 53.8; H, 4.0.

EXAMPLES 92-101 By the use of the general procedure of Example 91 and the substitution of other reactive alkyl halides or dialkyl sulfates the following exemplary compounds are obtained:

Example 92 N-methyl-3 -benzoyltrifluoromethanesulfonanilide 93 N-n-propyl-3-benzoyltrifluoromethanesulfonanilide 94 N-allyl-3-benzoyltrifluoromethanesulfonanilide 95 N-methyl-3 -benzoyldifluoromethanesulfonanilide 96 N-methyl-3 -benzoyl-4-hydroxytrifluorome thanesulfonanilide 97 N-methyl-3 -benzoylfluorochloromethanesulfonanilide Additional compounds of the invention prepared by the foregoing general procedures are as follows:

Example Meltin Point No. in. C. 102 3-(3-trifluorometh lbenzoyntrifluoromethanesu fonanilide; 86-88 103 3-(2-trifluorometh lbenzoyUtrifluoromethanesu fonamlide' -1 11 104 3- 4-trifluoromethoxybenzo l)tr|- uoromethanesulfonanili e 107-109 What is claimed is: l. A method for combatting inflammatory processes in a mammalian animal which comprises administering to said animal an effective dose less than the toxic amount of a compound of the formula:

I? C 4 1 i \X Ya wherein R is a haloalkyl group having up to 4 carbon atoms and at least one halogen atom bonded to the alpha carbon atom or if there is no halogen bonded to said alpha carbon atom, having at least 2 halogen atoms bonded to the beta carbon atom, R is-hydrogen, alkyl or alkenyl containing not more than three carbon atoms, or a pharmaceutically acceptable. cation; each Y is selected from hydroxy, halogen and alkyl, alkoxy, haloalkyl and haloalkoxy groups having up to 4 carbon atoms and n and n are each 0-3.

2. A method according to claim 1 wherein R: is CF;,.

3. A method according to claim 1 wherein R, is CF H.

4. A method according to claim 2 wherein n and n are zero.

5. A method according to claim 3 wherein n and n are zero.

6. A method according to claim 4 wherein R is hydrogen.

7. A method according to claim 4 wherein R is methyl.

8. A method according to claim 5 wherein R is hydrogen.

9. A method according to claim 5 wherein R is methyl.

10. A method according to claim :1 wherein the compound is 3-benzoylfluoromethanesulfonanilide.

11. A method according to claim 2 .wherein the compound is 3-benzoyl-4-hydroxytrifluoromethanesul' fonanilide.

12. A method according to claim 5 wherein the compound is the sodium salt of 3-benzoyldifluoromethanesulfonanilide.

13. A method according to claim 7 wherein the compound is N-methyl-3-benzoyltrifluoromethanesul1 fonanilide.

14. A method according to claim 8wherein the compound is 3-benzoyldifluoromethanesulfonanilide.

15. A method according to claim 1 wherein the compound is administered orally.

16. A method according to claim 3 wherein the compound is administered topically.-

17. A method accordingto claim 16 wherein the compound is 3-benzoyldifluoromethanesultonanilide. 

2. A method according to claim 1 wherein Rx is CF3.
 3. A method according to claim 1 wherein Rx is CF2H.
 4. A method according to claim 2 wherein n and n'' are zero.
 5. A method according to claim 3 wherein n and n'' are zero.
 6. A method according to claim 4 wherein R is hydrogen.
 7. A method according to claim 4 wherein R is methyl.
 8. A method according to claim 5 wherein R is hydrogen.
 9. A method according to claim 5 wherein R is methyl.
 10. A method according to claim 1 wherein the compound is 3-benzoylfluoromethanesulfonanilide.
 11. A method according to claim 2 wherein the compound is 3-benzoyl-4-hydroxytrifluoromethanesulfonanilide.
 12. A method according to claim 5 wherein the compound is the sodium salt of 3-benzoyldifluoromethanesulfonanilide.
 13. A method according to claim 7 wherein the compound is N-methyl-3-benzoyltrifluoromethanesulfonanilide.
 14. A method according to claim 8 wherein the compound is 3-benzoyldifluoromethanesulfonanilide.
 15. A method according to claim 1 wherein the compound is administered orally.
 16. A method according to claim 3 wherein the compound is administered topically.
 17. A method according to claim 16 wherein the compound is 3-benzoyldifluoromethanesulfonanilide. 